FDA, Genentech warn on Raptiva

The FDA announced new warnings on the Genentech psoriasis drug Raptiva following reports of four cases of hemolytic anemia diagnosed four to six months after patients started on the monoclonal antibody. Two of the cases occurred in clinical trials of Raptiva, and two were reported as post-marketing events, the FDA said.

- read this press release for more

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.